In Brief: Glaxo v. Novopharm ranitidine
This article was originally published in The Tan Sheet
Executive Summary
Glaxo v. Novopharm ranitidine: April 4 decision by Washington, D.C. federal appeals court upholds the Raleigh, N.C. lower court ruling that Novopharm's ANDA for generic ranitidine Form 1 does not violate Glaxo Wellcome's Zantac (ranitidine Form 2) patents. The appeals court heard oral arguments in Glaxo's appeal on Jan. 7 ("The Tan Sheet" Jan. 13, p. 19)...